Notizia - Recent Pharma, Healthcare and Biotech Happenings

Prometic bags USD 50 Million stock sale option to ease a cash crunch Prometic Life Sciences got into an agreement for selling USD 50 million in stock. This gives Prometic a way to escape its current financial pressures. Canada-based Prometic was asked by the FDA to make and validate process changes for Ryplazim, a congenital plasminogen deficiency treatment. The company reverted by contemplating to extend its financial runway, both by cutting costs and getting money into the business. The R&D costs are expected to plunge by USD 30 million in 2019. Vedanta receives USD 12 Million from Johnson & Johnson for the microbiome drug trial The collaboration of Vedanta B...